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Introduction
Malaria continues to be a global health problem, limiting economic growth and progress in high-burden 
communities. Nearly half  of  the world’s population is at risk for infection, with 219 million new cases 
reported in 2017, leading to nearly half  a million deaths per year. Malaria is caused by intracellular para-
sites of  the genus Plasmodium; of  these, Plasmodium falciparum is the most virulent form among the 5 species 
(P. vivax, P. ovale, P. malaria, and P. knowlesi) that infect humans (1). Malaria infection begins in the liver, an 
obligatory step where mosquito-delivered Plasmodium sporozoites invade hepatocytes and replicate within 
a parasitophorous vacuole. This affords the parasite the protection and resources to multiply from 1 initial 
infectious parasite into thousands of  daughter merozoites. These are then released to the bloodstream and 
go on to infect erythrocytes, commencing the symptomatic, cyclic, and pathogenic blood stage of  infection 
(2). Although clinically silent, the liver stage of  infection is a research priority because it is the first stage 
for stopping infection before fulminant disease. The liver stage of  malaria infection is also important for 
development of  sterile immunity and holds promise for vaccine development (3).
Traditional antimalarial drug discovery pipelines have been designed to target the Plasmodium parasite (4). 
However, current antimalarial interventions based on this approach have shortcomings, such as (a) restricted 
number of  effective drugs, (b) adverse side effects and restricted use, (c) development of  drug resistance, and 
(d) limited mechanisms of  action. For example, primaquine and tafenoquine, 8-aminoquinolines that target 
malaria liver stages, are the only drugs approved to treat P. vivax hypnozoites — the long-lived, dormant, 
hepatic forms that cause malaria relapses. However, their short half-life, long dosage regimens, and incom-
patibility with glucose-6-phosphate dehydrogenase deficiency (which requires prescreening of  recipients) 
makes them unsuitable for widespread use (5). Despite recent advances in novel parasite-directed antima-
larials, which hold much promise and are currently in the clinical pipeline, there is still a need for alternative 
approaches (6). Chemotherapy that targets the host, or both the host and the parasite, is a reasonable, comple-
mentary, and alternative approach to combat malaria because it would address several of  the shortcomings of  
current treatments, for example, by circumventing potential for generation of  drug-resistant parasites (7–10).
Despite an unprecedented 2 decades of success, the combat against malaria — the mosquito-
transmitted disease caused by Plasmodium parasites — is no longer progressing. Efforts toward 
eradication are threatened by the lack of an effective vaccine and a rise in antiparasite drug 
resistance. Alternative approaches are urgently needed. Repurposing of available, approved drugs 
with distinct modes of action are being considered as viable and immediate adjuncts to standard 
antimicrobial treatment. Such strategies may be well suited to the obligatory and clinically silent 
first phase of Plasmodium infection, where massive parasite replication occurs within hepatocytes 
in the liver. Here, we report that the widely used antidiabetic drug, metformin, impairs parasite 
liver stage development of both rodent-infecting Plasmodium berghei and human-infecting P. 
falciparum parasites. Prophylactic treatment with metformin curtails parasite intracellular growth 
in vitro. An additional effect was observed in mice with a decrease in the numbers of infected 
hepatocytes. Moreover, metformin provided in combination with conventional liver- or blood-
acting antimalarial drugs further reduced the total burden of P. berghei infection and substantially 
lessened disease severity in mice. Together, our findings indicate that repurposing of metformin in a 
prophylactic regimen could be considered for malaria chemoprevention.
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These approaches may lead to indirect effects on parasite replication or development through targeting 
of  processes essential for parasitism. Such mechanisms include limiting nutrient acquisition by the parasite 
or overcoming pathogen-imposed blocks in immune recognition and activation of  cell-intrinsic defense 
mechanisms, such as autophagy. Additionally, adjunct-directed therapy might help reduce collateral effects 
from infection, such as excessive inflammation leading to tissue damage. Additionally, adjunct-directed 
therapy may promote immune competence for effective parasite clearance and activation of  immune mem-
ory (7). Alternative targets that have been proposed as antimalarial interventions include erythrocyte G 
protein (11), heme oxygenase I (12, 13), CD81 and SRBI (14, 15), p53 and Bcl2 (16, 17), and several 
classes of  host kinases (18–20). Among these is the key regulator of  cell energy homeostasis, AMP kinase 
(AMPK) (20). In a previous work, we demonstrated that AMPK negatively modulates hepatic infection by 
Plasmodium parasites and that several AMPK-activating drugs cause a reduction in the intracellular growth 
of  rodent P. berghei parasites in vitro (20). In this study, we report on the in vivo antimalarial effect of  met-
formin, a known AMPK agonist widely used as an antidiabetic drug. We evaluated its potential use as a 
prophylactic and adjunctive treatment in combination with clinically approved antimalarials.
Results
Metformin treatment impairs P.berghei liver infection in mice. Metformin is the first-line treatment for type 2 
diabetes; it primarily targets the liver, where it acts to lower systemic blood glucose levels. In the liver, met-
formin can reach remarkably high levels with reported concentrations ranging between 60 μM (250 mg/
kg administered by drinking water) to 1 mM (350 mg/kg by oral gavage). This is in contrast with the 5 μM 
found in the plasma of  those animals (21). Metformin accumulation in the liver is due to the high expres-
sion of  organic cation transporters (OCTs) in the hepatocyte plasma membrane enabling drug import. This 
contributes to efficient reduction of  hepatic glucose production and output (22). Unlike hepatocytes, hepa-
toma cancer cells in vitro downregulate OCT expression (23, 24), which might affect effective drug dosing. 
Because our previous work was performed in a Huh7 hepatoma cell line (20), we decided to revisit the data 
and probe the activity of  metformin in freshly isolated primary mouse hepatocytes infected with rodent P. 
berghei sporozoites. We observed a 3-fold reduction of  the 50% inhibitory concentration (IC50) required to 
impair the parasite intracellular development in primary hepatocytes compared with hepatoma cells (45.17 
± 0.05 μM vs. 156 ± 70 μM, respectively; Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.127441DS1). This result prompted us to evaluate the 
in vivo efficacy of  metformin in a mouse model of  acute malaria. Metformin was administered to mice 
Figure 1. Metformin treatment inhibits P. berghei liver infection in mice. (A) Timeline of drug treatment, infection, and sample collection. C57BL/6 mice 
were injected intravenously with GFP-expressing P. berghei sporozoites (10,000 inoculum for B–D, 500 inoculum for E). Metformin (MET, 500 mg/kg/d) 
was given prophylactically in the drinking water 1 week before and during infection. Nontreated control (CTL) received regular water. Livers were harvested 
at 42 hours and tail blood was collected 72 hours after infection. (B) Representative immunofluorescence images of P. berghei schizonts in liver sections at 
42 hours after infection. Parasites were visualized using anti-GFP (not shown) to detect the reporter transgene and anti-PbUIS4, a parasitophorous mem-
brane marker (shown in red). Nuclei were stained with Hoechst (shown in blue). Scale bar: 10 μm. (C) Box plot of P. berghei size distribution in liver sections 
at 42 hours. The total number of parasites analyzed in 3 infected mice per group is 377, CTL; and 115, MET. The outliers in the box plots represent 5% of 
data points. The box plots depict the minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box 
represents the interquartile range. Mann-Whitney U test, ****P < 0.0001. (D) Scatter plot of parasite density per square micrometer of infected liver sec-
tions at 42 hours. Each dot represents one animal and the horizontal bar represents the mean. Student’s t test, ***P < 0.001. (E) Scatter plot showing the 
percentage of infected erythrocytes (parasitemia) measured by flow cytometry 72 hours after infection. Each dot represents 1 animal and the horizontal 
bar represents the mean. The total number of mice analyzed in 2 independent experiments is 9, CTL; and 10, MET. Mann-Whitney U test, ****P < 0.0001.
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orally via drinking water at approximately 500 mg/kg/d, a dose previously validated in mice infected with 
Mycobacterium tuberculosis (25). Metformin treatment over a week resulted in plasma concentrations of  3–7 
μM, which is comparable to levels previously reported in mice (21) and diabetic patients under treatment 
(26). No differences in water intake and body weight were observed between the treated and nontreated 
animals (Supplemental Figure 2). Mice treated for a week were then infected by intravenous injection of  
P. berghei sporozoites (Figure 1A). The livers of  infected mice were harvested 42 hours after infection, 
sectioned, and analyzed by fluorescence microscopy using parasite-specific markers. Consistent with our 
previous in vitro data (20), we observed that individual hepatic schizonts in metformin-treated mice were 
dramatically smaller than those in nontreated mice (492 ± 167 μm2 vs. 140 ± 63 μm2; P < 0.0001; Figure 1, 
B and C). Additionally, microscopy analysis revealed that the number of  infected hepatocytes was signifi-
cantly reduced in metformin-treated relative to the nontreated control mice (378 ± 31 parasites/μm2 vs. 108 
± 29 parasites/μm2; P < 0.001; Figure 1D). To assess the global impact of  metformin treatment, we infected 
mice with 500 sporozoites, an inoculum that is expected to mimic a natural infection by a mosquito bite 
(27, 28), and allowed the entire liver stage development to be completed. We then determined the prepatent 
parasitemia by flow cytometry analysis 72 hours after infection. Strikingly, while the entire group of  non-
treated mice presented with parasites in the blood, we were unable to detect P. berghei–infected erythrocytes 
in 40% of  the metformin-treated mice (Figure 1E). The remaining 60% of  mice showed an 87% reduction 
in parasitemia levels relative to the nontreated control (P < 0.0001; Figure 1E). These results show that 
metformin has a potent activity against liver stage malaria in vivo.
Metformin treatment reduces P. falciparum growth in human hepatocytes. Next, we sought to validate 
our findings in a more clinically relevant P. falciparum infection model. Cryopreserved primary human 
hepatocytes were maintained in micropatterned cocultures in vitro containing supportive fibroblasts 
(29–32), infected with P. falciparum sporozoites, and treated daily with metformin (Figure 2A). Con-
sistent with the P. berghei experiments, metformin treatment reduced the intracellular development of  
P. falciparum parasites, in a dose-dependent manner, as seen by a significant decrease in the mean size 
of  hepatic schizonts at day 4 after sporozoite infection (P < 0. 0001; Figure 2, B and C). Unlike the 
data obtained in mice, however, we did not observe significant differences in the number of  infected 
hepatocytes (Figure 2D). This discrepancy might be due to antiinflammatory alterations promoted by 
metformin in vivo (25, 33), which might lead to efficient clearance of  liver stage Plasmodium parasites, 
or a defect in parasite hepatocyte invasion due to pretreatment.
Figure 2. Metformin treatment reduces P. falciparum development in human hepatocytes. (A) Timeline of metformin 
treatment, infection, and sample collection. Primary human hepatocytes were infected with 60,000 P. falciparum 
sporozoites. Prophylactic dosing of metformin (50 and 200 μM) started at 3 hours after infection and repeated daily. 
Cultures were fixed at day 4 after infection. (B) Representative immunofluorescence images of P. falciparum parasites 
stained with anti-PfHSP70 antibodies (shown in red) for nontreated control and 200 μM metformin treatment. Nuclei 
were stained with Hoechst (shown in blue). Scale bar: 5 μm. (C and D) Quantification of P. falciparum size distribution 
(C) and density (D) at day 4 after infection. The total number of parasites analyzed in 2 independent experiments is 
190, CTL; 143, MET 50 μM; 140, MET 200 μM. The outliers in the box plots represent 5% of data points. The box plots 
depict the minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The length of the 
box represents the interquartile range. The dots in the scatter plot represent 1 well, and the horizontal bars show the 
mean, in 1 of the 2 experiments. Ordinary 1-way ANOVA test, ****P < 0.0001.
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Metformin treatment is inefficient in Plasmodium asexual erythrocytic stages. To evaluate the curative potential 
of  metformin on symptomatic blood stage infection, we determined dose-response curves in P. falciparum 
blood cultures and monitored the parasitemia in treated and nontreated mice infected with P. berghei sporo-
zoites. For the in vitro sensitivity studies, synchronized blood cultures of  P. falciparum were exposed to esca-
lating doses of  metformin and compared with the nontreated condition. Parasite growth inhibition curves 
determined after a 48-hour incubation showed an IC50 value considerably higher than that of  liver stages in 
vitro (3.7 ± 1.1 mM vs. 45.17 ± 0.05 μM, respectively; Supplemental Figure 3A). In mice infected with a 
natural inoculum of  sporozoites (as above), we observed similar growth in the linear phase of  replication 
(days 3–5 of  patent blood stage infection), with no significant difference in the calculated parasite multipli-
cation rate between nontreated and metformin-treated animals (Supplemental Figure 3B). Collectively, our 
results suggest a weak effect of  metformin on infected erythrocytes, which is in agreement with historical 
data reporting no effect in patients with an ongoing P. vivax blood stage infection (34). Furthermore, a recent 
study showed similar parasitemia in nontreated and metformin-treated mice infected with P. yoelii (35).
Metformin adjunctive treatment enhances effect of  antimalarial drugs. Given the robust inhibitory effect of  met-
formin treatment on both P. berghei and P. falciparum infections in the liver, we next explored whether combi-
nation with suboptimal doses of  conventional antimalarial drugs that are more likely to result in fewer side 
effects could improve the effectiveness of  the prophylactic treatment. First, we tested a combination of  met-
formin with primaquine, a drug targeting liver stage parasites. Mice were pretreated with metformin in drink-
ing water and infected with 500 P. berghei sporozoites (as above). A single suboptimal dose of  primaquine 
was then administered via intraperitoneal injection to nontreated and metformin-treated mice. The end result 
of  liver infection was detected 72 hours after infection by assessing the number of  infected erythrocytes by 
flow cytometry (Figure 3A). Although the entire group of  nontreated mice exhibited prepatent parasitemia, 
the combined treatment of  metformin and primaquine resulted in a remarkable inhibition of  liver infection, 
with only 10% of mice showing parasites in blood (Figure 3B). The outcome of  the single-drug treatments 
was 30% and 90% blood positive for primaquine and metformin, respectively (Figure 3B and Table 1).
Next, we evaluated the combined effect of  metformin with a suboptimal dosage of  mefloquine, one 
of  the most used drugs for antimalarial prevention in travelers, despite the numerous side effects, such as 
headaches, dizziness, insomnia, and psychological disturbances (36). Unlike primaquine, mefloquine is 
active against blood stages of  malaria parasites but not liver stages. Mefloquine was administered by daily 
intraperitoneal injections starting on the day of  infection with sporozoites and was continued up to day 5 
(Figure 3A). As expected, the single or combined mefloquine treatment did not affect the total parasite load 
measured at 72 hours when compared to nontreated mice or metformin treatment alone (Figure 3B). As the 
parasites continued proliferating in the blood, mefloquine inhibitory activity became evident. Specifically, 
we observed that parasitemia was significantly lower in mice with the combined treatment relative to mice 
Figure 3. Combined metformin treatment with suboptimal doses of primaquine or mefloquine improves antimalarial effect. (A) Timeline of drug treat-
ments, infections, and sample collection. C57BL/6 mice were injected intravenously with 500 GFP-expressing P. berghei sporozoites. Metformin (500 mg/
kg/d) was provided in the drinking water 1 week before and during infection. Primaquine (PQ, 15 mg/kg) was injected 1 time intraperitoneally 2 hours after 
infection. Mefloquine (MQ, 10 mg/kg) was given daily by intraperitoneal injection. (B and C) Scatter plot showing the percentage of infected erythrocytes 
(parasitemia) measured by flow cytometry at day 3 (72 hours, B) and day 5 (C) after infection. Each dot represents 1 animal. The horizontal bar represents 
the mean. The total number of mice analyzed is as follows: 10, CTL; 10, MET; 10, PQ; 10, MET/PQ; 5, MQ; and 5, MET/MQ. P values calculated relative to 
nontreated CTL (B) and relative to MET (C). Ordinary 1-way ANOVA test, ****P < 0.0001; **P < 0.01; *P < 0.05; ns, not significant.
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under mefloquine or metformin single-drug treatments (P = 0.013 and P = 0.041; Figure 3C). Of note, mice 
under single or combined metformin treatments showed an extended survival, whereas 84% of  the nontreat-
ed mice succumbed within 1 week after infection (Table 1). In conclusion, metformin treatment in combi-
nation with suboptimal dosage of  conventional antimalarials is more efficacious in reducing parasite load.
Discussion
Metformin is listed by the World Health Organization as an essential medicine to treat and prevent type 2 
diabetes. As a biguanide, metformin is related to guanidine and galegine, which can both be extracted from 
goat’s rue (Galega officionalis). This medicinal plant was traditionally used in medieval Europe as a treat-
ment for diabetes and other ailments, including infections such as the plague and typhoid fever. Metformin 
was first synthesized in 1922, but its use as an antidiabetic agent was only proposed in 1957, a discovery 
closely linked to malaria owing to the structural relatedness of  metformin to proguanil, a highly potent 
antimalarial biguanide. In the 1940s, metformin was tested in patients with an ongoing malaria blood 
stage infection while a search was underway for alternatives to proguanil, which was becoming ineffective 
because of  parasite resistance (34, 37). Although no clear effect on parasitemia was found (34), lowered 
glucose levels were later noticed after metformin treatment (37). Indeed, the antihyperglycemia property 
appears to be common to most biguanides, but metformin outperforms with minimal lactic acidosis.
With a long track record of clinical use, metformin has proved to be highly tolerable, with a strong safety 
profile and few interactions with other medications. In addition, metformin is water-soluble, is orally bioavail-
able, has excellent pharmacokinetic adsorption and excretion properties, and has a low cost of production, 
making it highly affordable and accessible (37, 38). These properties contribute to metformin’s qualifications 
as an optimal drug for repurposing (39). Interest in metformin repurposing has been sparked in recent years 
because of numerous epidemiologic observations and meta-analyses demonstrating positive outcomes and 
improved prognosis in diabetes patients diagnosed with cancer. To date more than 100 clinical trials in oncolo-
gy are underway to determine the benefits of metformin as adjunctive therapy in treating and preventing cancer 
and longevity-related causes, such as inflammation, senescence, and oxidative damage (39–41). It is also being 
studied as a potential adjunctive therapy to treat infections such as tuberculosis (25, 42) and AIDS (43).
The mechanism of  action of  metformin is not fully defined because it appears to have multiple pleio-
tropic direct and indirect effects on various cell processes and cell targets. In the treatment of  diabetes, 
metformin is widely used to decrease glucose production and output from the liver and increase circulating 
insulin sensitivity. These effects are thought to be a result of  metformin’s interaction with mitochondria, 
where it alters cellular bioenergetics by inhibiting the respiratory chain complex I. This leads to a decrease in 
oxidative phosphorylation and subsequent drop in energy with altered ADP-to-ATP ratios (22, 44, 45). As a 
consequence, several pathways are affected, such as through the activation of  the energy sensor AMPK and 
a shutdown in gluconeogenesis (46–48). AMPK-dependent processes that are altered include suppression 
of  mTOR and insulin receptor signaling (IGF-I) via PI3K/AKT pathways, leading to decreased protein 
synthesis and cell growth and increased apoptosis and autophagy (49). Other mechanisms independent of  
Table 1. Prepatency and survival of nontreated and treated mice
Prepatency Survival
Day 3 Day 5 Day 10
No treatment 19 (19) 19 (19) 3 (19)
Metformin 17 (20) 19 (20) 16 (20)
Primaquine 3 (10) 3 (10) 10 (10)
Metformin/Primaquine 1 (10) 6 (10) 10 (10)
Mefloquine 5 (5) 5 (5) 5 (5)
Metformin/Mefloquine 4 (5) 3 (5) 5 (5)
Summary of C57BL/6 mice infected with GFP-expressing P. berghei sporozoites and treated with metformin, 
primaquine, and mefloquine, alone or in combination as described in Figures 1 and 3. Prepatency was determined by 
detecting the presence of GFP+ red blood cells via flow cytometry analysis. The number of mice carrying parasites on 
days 3 (72 hours) and 5 after sporozoite injection is shown. The total number of infected mice is given in parentheses. 
The number of mice alive on day 10 is also shown.
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AMPK include direct suppression of  regulators such as mTOR at higher metformin concentrations to inhib-
it hepatic protein synthesis (50), as well as stabilization and induction of  p53, which inactivates cyclin D1 
and retinoblastoma proteins to inhibit proliferation and promote apoptosis (51–53). Metformin also leads 
to a reduction in gluconeogenesis and direct inhibition of  mitochondrial glycerophosphate dehydrogenase 
and other mitochondria-dependent biosynthetic pathways, leading to an altered redox state, inhibition of  
mitochondrial respiration, and availability of  macromolecules (54, 55).
In the context of  suppressed liver stage Plasmodium infection reported in this study, it remains to be 
determined whether metformin is targeting the host or both the host and the parasite. Potential mechanisms 
and targets on the host cell include the aforementioned anticancer processes demonstrated to be executed 
by metformin, such as increased AMPK and p53 signaling and decreased AKT signaling, because these 
pathways have previously been described to alter infection (16, 17, 20, 56). Of  particular interest is the 
concept that infected hepatocytes undergo a metabolic switch with pro-proliferative tendencies that allow 
parasite growth (7, 20). Consistent with our in vitro and in vivo data of  reduced intrahepatic schizont size 
under metformin treatment, a shutdown of  a pro-proliferative program within the host cell would limit 
parasite growth. In addition to suppression of  pro-proliferative pathways during liver stage infection, met-
formin could also promote cell-autonomous host defense mechanisms, such as increased apoptosis, auto-
phagy, lysosome-vacuole fusion, type I interferon signaling, and reactive oxygen species–mediated killing, 
all of  which have been shown to induce parasite killing and clearance of  Plasmodium-infected hepatocytes 
via infiltrating phagocytes (57–60). Similar metformin-mediated mechanisms have been described for other 
intracellular pathogens, such as M. tuberculosis (25), Legionella pneumophilia (61), and hepatitis C virus (62).
Metformin has also been shown to mediate immune modulation, such as enhanced T and B cell effec-
tor functions and memory (63–65). Interestingly, a recent study showed that metformin had an effect on the 
host immunity leading to partial protection of  rodents infected with P. yoelii blood stages (35). Although 
Miyakoda et al. focused on the erythrocytic infection, the effect of  metformin on the immune system would 
be worth exploring within the context of  the liver microenvironment, as would a potential role in vaccine 
development and sterile immunity (66). Future work should also consider a potential metformin-mediated 
effect on the Plasmodium parasite. The antimalarial proguanil, also a biguanide, works synergistically with 
atovaquone (another antimalarial) to target the parasite mitochondrial electron transport chain, and when 
metabolized into cycloguanil (a triazine), directly targets the parasite dihydrofolate reductase enzyme (67). 
Metformin is not metabolized, but one cannot exclude that unchanged metformin can target the parasite 
directly. It would be interesting to determine the subcellular localization of  metformin, both in infected 
hepatocytes and erythrocytes, using fluorophores and click chemistry (68). Growth inhibition assays using 
parasite mutants for potential metformin targets (e.g., mitochondrial components or the AMPK homolog, 
KIN; ref. 69) may also provide insights into the mechanism by which metformin operates.
In summary, our results provide compelling evidence for the chemopreventive potential of  using met-
formin in the context of  malaria infections, whose potential can be enhanced by combination with con-
ventional antimalarials, with the purpose of  reducing their dose and associated side effects. Although 
encouraging, we acknowledge that the doses used in our mice and in vitro assays might not be helpful 
at predicting the drug concentration required for antimalarial prophylactic activity in humans. This is an 
unfortunate limitation of  using mouse and in vitro models to assess the clinical relevance of  metformin 
(21, 70). It remains unclear why rodents require administration of  higher metformin doses to reach plas-
ma concentrations comparable to those of  patients with diabetes under a standard clinical dose. Never-
theless, the presented data represent a proof  of  concept for repurposing of  an oral agent with an excellent 
track record for safety and tolerability. Another advantage of  metformin as an adjuvant therapy is that it 
is already approved and a candidate drug already in clinical trials as adjuvant therapy in other infectious 
diseases, as well as cancer. Thus, the use of  metformin warrants future clinical studies to assess efficacy, 
safety, and potential as a prophylactic antimalarial.
Methods
Chemicals. Metformin (catalog D150959), Metformin-(dimethyl-d6) hydrochloride (catalog 53183), pri-
maquine bisphosphate (catalog 160393), and mefloquine hydrochloride (catalog M2319) were purchased 
from MilliporeSigma.
Antibodies. Anti-PbUIS4 goat polyclonal was purchased from SICGEN (AB0042-200). Anti-PfHSP70 
mouse monoclonal (4C9) was a gift from Fidel Zavala (John Hopkins University, Baltimore, Maryland, USA).
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Parasite lines. Transgenic P. berghei ANKA parasites expressing GFP (259cl2) and GFP/luciferase 
(676m1cl1) were obtained from the Leiden Malaria Research Group (www.pberghei.eu). Transgenic P. berghei 
ANKA sporozoites were isolated from salivary glands of  Anopheles stephensi mosquitoes bred at Instituto de 
Medicina Molecular João Lobo Antunes (Lisboa, Portugal). P. falciparum NF54–infected Anopheles stephensi 
mosquitoes were obtained from John Hopkins University Malaria Research Institute (Baltimore, Maryland, 
USA) or Sanaria Inc (Rockville, Maryland, USA). Cryostabilates of  P. falciparum 3D7–infected erythrocytes 
were obtained through the MR4 (https://www.beiresources.org/About/MR4.aspx).
Animals, drug treatments, and infections. Male C57BL/6 mice 6–8 weeks old were purchased from 
Charles River Laboratories, Inc, and housed in specific pathogen–free facilities of  the Instituto de Medici-
na Molecular João Lobo Antunes (Lisboa, Portugal). Mice were infected with freshly dissected P. berghei 
sporozoites by intravenous injection, with the inoculum of  500 or 10,000 as indicated in the correspond-
ing figure legend. For all drug treatments, mice were weighed to determine appropriate dosage, which was 
adjusted accordingly. Metformin was administered prophylactically starting at day –7 via drinking water 
to a final dose of  500 mg/kg/d (~2.5 mg/mL as determined by mouse weight and daily water intake vol-
ume per mouse). Primaquine was dissolved in 0.9% NaCl at a dose of  15 mg/kg in a total volume of  200 
μL and administered as a single dose at 2 hours after sporozoite inoculation by intraperitoneal injection. 
The suboptimal dose of  primaquine was determined based on previous studies (71, 72). Mefloquine was 
dissolved 1% methanol (v/v) in 0.9% NaCl in a total volume of  400 μL and injected by intraperitoneal 
injection daily starting on the day of  sporozoite inoculation and up to day 5 after infection (73).
Cell culture and infection. Primary mouse hepatocytes were isolated using a 2-step in situ perfusion method, 
as described previously (20). Percoll-purified hepatocytes were seeded in collagen-coated 96-well plates and 
infected the day after with freshly dissected P. berghei sporozoites (8000/well). Metformin was added 2 hours 
after infection in increasing concentrations (in triplicate) for IC50 determination to generate an 8-point dose 
response. IC50 values were calculated by fitting the data to a log dose-response curve using GraphPad (Prism).
Cryopreserved primary human hepatocytes purchased from BioIVT were seeded on collagen-mi-
cropatterned 96-well plates, as described previously (29, 32). Hepatocytes were infected with freshly 
dissected P. falciparum sporozoites (60,000/well), and metformin was added 3 hours later at 50- and 
200-μM final concentrations.
P. falciparum blood cultures were maintained in RPMI supplemented with 25 mM HEPES, 100 μM 
hypoxanthine, 2 mM l-glutamine, 50 μg/L gentamicin, and 0.5% albumax II and 2% hematocrit. The in 
vitro drug assay was performed in 96-well plates. Metformin was added in duplicate with a series of  2-fold 
dilutions, and starting parasitemia was adjusted to 0.1%. Parasitemia was measured by flow cytometry at 
48 hours after drug exposure, and IC50 values were determined as described above.
Luminescence and cell viability assays. Primary mouse hepatocytes were washed with PBS at 48 hours after 
infection and lysed for 20 minutes in 75 μL of  lysis buffer from Firefly Luciferase Assay Kit (Biotium). Fifty 
microliters of  d-Luciferin dissolved in the kit buffer was added to 30 μL of  total lysate in white 96-well plates, 
and luminescence was measured using a multiplate reader (Infinite 200M, Tecan). Cell viability was assayed 
by CellTiter Blue cell viability assay (Promega) using the manufacturer’s protocol, following an incubation 
of  90 minutes at 37°C, and fluorescence was measured with a multiplate reader (Infinite 200M, Tecan).
Immunofluorescence assay. The median lobes of  livers were fixed with 4% paraformaldehyde for 2 hours 
and sliced into 50-μm thick sections using the Vibratome VT 1000 S (Leica). To detect P. berghei parasites, liv-
er sections were permeabilized and blocked in 1% BSA and 0.3% Triton X-100 for 45 minutes and incubated 
with goat anti-PbUIS4 antibodies for 1 hour at room temperature. After washing, liver sections were incu-
bated with anti-goat conjugated to Alexa Fluor 555 (Thermo Fisher Scientific, catalog A21432), anti-GFP 
conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, catalog A21311), and Hoechst (Thermo Fisher 
Scientific, catalog 33258) for another 1 hour at room temperature. Hoechst 33258 (H3569) was obtained 
from Thermo Fisher Scientific. Finally, 6–8 sections representing an equal distribution of  lobe per mouse 
were mounted in Fluoromount (Southern Biotech) and imaged on an Axiovert 200M (Zeiss). For analysis, 
the entire section was scanned, and images of  parasites were recorded. Parasite area was quantified with 
ImageJ software (NIH) based on GFP and PbUIS4 staining.
Primary human hepatocytes were fixed in cold methanol for 10 minutes and stored at 4°C after PBS 
washing. To detect P. falciparum parasites, cells were blocked in 2% BSA for 30 minutes and incubated with 
anti-PfHSP70 monoclonal antibodies (4C9) for 1 hour at room temperature. Cells were then washed in 
PBS and incubated with anti-mouse conjugated to Alexa Fluor 594 (Thermo Fisher Scientific, A-21203) 
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for 1 hour at room temperature. Next, cells were counterstained with Hoechst and mounted in Aqua-
mount (Thermo Scientific, catalog 41799-008). Images of  all parasites in the well were captured on a Nikon 
Eclipse Ti microscope and analyzed with ImageJ.
Flow cytometry. A drop (2–3 μL) of  blood was collected from the mouse tail, placed into 500 μL PBS, 
and analyzed in an LSR Fortessa flow cytometer (BD Biosciences). Per mouse, 1–2 million events were 
acquired at the indicated time points. BD FACSDiva software was used for data acquisition and FlowJo 
software for further analysis. Cells were selected on the basis of  their size by gating first on FSC and SSC 
and, subsequently, plotted on FITC (green) and PE (red) channels to eliminate autofluorescent events. The 
GFP-expressing parasites were detected in the FITC channel.
Metformin quantification. Naive mice, treated with 500 mg/kg in drinking water as described above for 7 
days, were bled by heart puncture for plasma preparation into K2EDTA tubes. Plasma samples were stored at 
–80°C until analysis at Mass Spectrometry Unit, Instituto de Tecnologia Química e Biologia/Instituto de Bio-
logia Experimental e Tecnológica (Oeiras, Portugal). Briefly, metformin and metformin-D6 standard solutions 
were prepared in 50% acetonitrile/water. Samples were prepared by adding 47.5% acetonitrile and 2.5 μM 
metformin-D6 to 40 μL of plasma, followed by centrifugation at 18,000 g for 10 minutes at 1°C. A standard 
calibration curve was prepared similarly to the samples, with a series of 2-fold dilutions of metformin spiked 
in 20 μL of nontreated plasma. Sample and standard injections (1 μL) were performed in triplicate. Chromato-
graphic analysis was performed on an Ultimate 3000 UHPLC and the separation on a Waters XBridge column 
C18 (2.1 × 150 mm, 3.5-μm particle size). The mobile phases A and B were water and acetonitrile with 0.1% 
formic acid, respectively. Column temperature was maintained at 30°C and flow rate at 400 μL/min. The data 
were acquired on the Q Exactive Focus coupled to UHPLC, using Xcalibur software v.4.0.27.19.
Statistics. Statistics were determined with Student’s t (2 tailed) and Mann-Whitney U tests for compari-
sons between 2 conditions and 1-way ANOVA for comparisons involving 3 or more conditions. All samples 
were included in the analysis. P values below 0.05 were considered statistically significant. Data mentioned 
in the text are represented as mean ± SD.
Study approval. Experimental procedures were approved by the internal Animal Ethics Committee and 
performed in accordance with the Portuguese law for the use of  laboratory animals (Decree-Law 113/2013), 
the European Directive 2010/63/EU, and the Federation of  European Laboratory Animal Science Associ-
ations guidelines and recommendations concerning laboratory animal welfare. The primary human hepato-
cytes used in this study are commercially available. Approvals and certificates were obtained by the vendors.
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